Advertisement
UK markets close in 1 hour 28 minutes
  • FTSE 100

    8,194.75
    +52.60 (+0.65%)
     
  • FTSE 250

    20,370.02
    +210.30 (+1.04%)
     
  • AIM

    778.28
    +3.35 (+0.43%)
     
  • GBP/EUR

    1.1831
    -0.0004 (-0.03%)
     
  • GBP/USD

    1.2712
    +0.0008 (+0.06%)
     
  • Bitcoin GBP

    50,980.31
    -264.96 (-0.52%)
     
  • CMC Crypto 200

    1,348.87
    -40.53 (-2.92%)
     
  • S&P 500

    5,481.76
    +8.53 (+0.16%)
     
  • DOW

    38,857.39
    +79.29 (+0.20%)
     
  • CRUDE OIL

    80.90
    +0.57 (+0.71%)
     
  • GOLD FUTURES

    2,339.30
    +10.30 (+0.44%)
     
  • NIKKEI 225

    38,482.11
    +379.67 (+1.00%)
     
  • HANG SENG

    17,915.55
    -20.57 (-0.11%)
     
  • DAX

    18,109.94
    +41.73 (+0.23%)
     
  • CAC 40

    7,616.88
    +45.31 (+0.60%)
     

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

Neurocrine Biosciences continues to put up really healthy numbers, with an ostensible 335% profit hike on a powerful reversal last quarter. On Friday, Neurocrine Biosciences stock got a Relative Strength (RS) Rating upgrade from 77 to 82. The upgraded 82 RS Rating means Neurocrine Biosciences stock is among the top 18% overall for price performance over the past year.